The Study of Drug SCT510A in Patients With Wet Age-related Macular Degeneration (wAMD)
NCT04564937 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 66
Last updated 2020-09-25
Summary
Multicenter ，open-label, multi-dose study to evaluate the safety and tolerability in patients with wAMD treated with intravitreal recombinant humanized anti-VEGF monoclonal antibody（SCT510A）
Conditions
Interventions
- DRUG
-
SCT510A
SCT510A of 0.625mg、1.25mg、2.0mg、2.5mg,IVT
Sponsors & Collaborators
-
Sinocelltech Ltd.
lead INDUSTRY
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SEQUENTIAL
Eligibility
- Min Age
- 45 Years
- Max Age
- 80 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2020-11-06
- Primary Completion
- 2022-04-30
- Completion
- 2022-10-31
More Related Trials
-
Multicenter, Phase I/II Study to Evaluate the Safety, Tolerability, PK and Efficacy of SCT520FF in Patients With nAMD
NCT06672536 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
A Study to Evaluate the Efficacy and Safety of MW02 in the Treatment of nAMD
NCT05297292 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
A Clinical Study Evaluating the Safety and Efficacy of SKG0106 in Patients With Neovascular Age-related Macular Degeneration (nAMD)
NCT06213038 ·Status: RECRUITING ·Phase: PHASE1
-
A Study of Single Intravitreal Injection HB002.1M in Subjects With Neovascular Age-Related Macular Degeneration
NCT03387566 ·Status: COMPLETED ·Phase: PHASE1
-
A Long-term Follow up Study of EXG102-031 in Participants With wAMD
NCT06859515 ·Status: RECRUITING
-
Seven-year Outcomes Following Intensive Anti-VEGF Therapy in Wet AMD
NCT05678517 ·Status: COMPLETED
-
Phase 1 Study of CM082 in Patients With wAMD
NCT02452385 ·Status: SUSPENDED ·Phase: PHASE1
-
Safety and Tolerability of Oral CM082 in Patients With wAMD
NCT03710863 ·Status: UNKNOWN ·Phase: PHASE2
-
Safety and Tolerability of AL-001 Ophthalmic Injection in Subjects with WAMD
NCT06707753 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Pharmacogenomic Study on Anti-VEGF Medicine in Treatment of Macular Neovascular Diseases
NCT03128463 ·Status: UNKNOWN
-
A Long-term Follow-up Study to Evaluate SKG0106 in the Treatment of Patients With nAMD
NCT06346600 ·Status: RECRUITING
-
Clinical Study Of Pegaptanib Sodium (EYE001) For Wet-Type Age-Related Macular Degeneration
NCT00239928 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Efficacy Study of LX102-C01 Treatment of Neovascular Age-Related Macular Degeneration (nAMD)
NCT05831007 ·Status: UNKNOWN ·Phase: NA
-
To Evaluate the Safety and Preliminary Efficacy of Intravitreal EXG202 Injection in Patients with Wet (neovascular) Age-related Macular Degeneration (wAMD)
NCT06888492 ·Status: NOT_YET_RECRUITING ·Phase: EARLY_PHASE1
-
Study to Assess Safety and Tolerability of PMC-403 in Subjects With Neovascular Age-related Macular Degeneration
NCT05953012 ·Status: COMPLETED ·Phase: PHASE1
-
Sirolimus Versus Anti-Vascular Endothelial Growth Factor (antiVEGF) for Wet AMD
NCT02357342 ·Status: COMPLETED ·Phase: PHASE2
-
Safety, Tolerability and PK of Subcutaneous D-4517.2 in Subjects With Wet AMD or DME
NCT05387837 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Evaluate the Safety and Efficacy of HLX04-O in Subjects With wAMD
NCT04993352 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of D-4517.2 After Subcutaneous Administration in Healthy Participants
NCT05105607 ·Status: COMPLETED ·Phase: PHASE1
-
Identification of Molecular Signals in Vitreous Humor Associated With Suboptimal Response to Vascular Endothelial Growth Factor (VEGF) Inhibition in Neovascular Age-related Macular Degeneration (nAMD) Within a Clinical Trial Setting
NCT07249216 ·Status: RECRUITING ·Phase: NA
-
TAB014(Drug Code) in Wet( Neovascular)Age-related Macular Degeneration(AMD) Subjects
NCT03675880 ·Status: UNKNOWN ·Phase: PHASE1
-
Gene Therapy for Wet AMD
NCT05611424 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1
-
Real World Evidence in China: Faricimab Use in Diabetic Macular Edema, Retinal Vein Occlusion, and Neovascular Age-Related Macular Degeneration (The Farseeing Study)
NCT06439576 ·Status: ACTIVE_NOT_RECRUITING
-
A Study to Assess the Safety, Tolerability and Effectiveness of MT-0814 for the Treatment of Age-related Macular Degeneration
NCT03869684 ·Status: TERMINATED ·Phase: PHASE2
-
Phase I/II Study of SKG0106 Intravitreal Injection in Patients With Neovascular Age-related Macular Degeneration (nAMD)
NCT05986864 ·Status: RECRUITING ·Phase: PHASE1/PHASE2